Prosecution Insights
Last updated: August 16, 2026

Nanjing Genscript Biotech Co. Ltd.

10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
7
Non-Final OAs
2
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

5
Hard (50%)
3
Medium (30%)
2
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (10%)
§103 only2 (20%)
§112 only2 (20%)
Double-patenting + other1 (10%)
Multi-statute (no §101)4 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
70% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
3
Business / Other
30% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KENNEDY, SARAH JANE 1 0.0% +0.0%
BENAVIDES, JENNIFER ANN 1 51.3% +48.6%
WASHINGTON, BRITNEY NICOLE 1 85.1% +17.0%
WONG, EDNA 1 58.6% -19.2%
MYERS, CARLA J 1 49.0% +46.6%
PERSONS, JENNA L 1 50.0% +60.0%
LU, CHENG 1 53.7% +66.2%
CHONG, KIMBERLY 1 72.4% +12.8%
FLINDERS, JEREMY C 1 63.7% +16.7%
CUNNINGCHEN, KATHLEEN MARY 1 60.4% +64.8%

Hard Cases (5)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18718992 METHOD FOR DETECTING INTEGRATION SITE KENNEDY, SARAH JANE
18396656 AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR WASHINGTON, BRITNEY NICOLE
18287245 PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS MYERS, CARLA J
18279811 DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM CHONG, KIMBERLY
17624505 ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CUNNINGCHEN, KATHLEEN MARY

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17758048 Method For Constructing Gene Mutation Library FLINDERS, JEREMY C 8d
18682827 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a BENAVIDES, JENNIFER ANN
18396656 AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR WASHINGTON, BRITNEY NICOLE
18287245 PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS MYERS, CARLA J
18286880 PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF PERSONS, JENNA L
18281849 ANTIBODY FUSION PROTEINS AND USES THEREOF LU, CHENG
18279811 DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM CHONG, KIMBERLY
17624505 ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CUNNINGCHEN, KATHLEEN MARY

Top Art Units

Art UnitApps
1795 1
1682 1
1637 1
1642 1
1636 1
1684 1
1646 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18718992 METHOD FOR DETECTING INTEGRATION SITE KENNEDY, SARAH JANE §103§112Other Non-Final OA Pending Jun 12, 2024
18682827 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a BENAVIDES, JENNIFER ANN §112 Non-Final OA Pending Feb 09, 2024
18396656 AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR WASHINGTON, BRITNEY NICOLE §102§103 Non-Final OA Pending Dec 26, 2023
18565339 ELECTROGRAFTED FILMS FOR DNA SYNTHESIS WONG, EDNA 1795 §112 Final Rejection 43d Pending Nov 29, 2023
18287245 PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS MYERS, CARLA J 1682 §101§102§103§112DP Non-Final OA Pending Oct 17, 2023
18286880 PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF PERSONS, JENNA L 1637 §102§103§112DPOther Non-Final OA Pending Oct 13, 2023
18281849 ANTIBODY FUSION PROTEINS AND USES THEREOF LU, CHENG 1642 §103 Non-Final OA Pending Sep 13, 2023
18279811 DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM CHONG, KIMBERLY 1636 §102§103§112 Non-Final OA Pending Aug 31, 2023
17758048 Method For Constructing Gene Mutation Library FLINDERS, JEREMY C 1684 §103 Non-Final OA 8d Pending Jun 27, 2022
17624505 ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CUNNINGCHEN, KATHLEEN MARY 1646 §103§112 Final Rejection Pending Jan 03, 2022

Managing Nanjing Genscript Biotech Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month